Vedanta Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Vedanta Biosciences, a clinical-stage biopharmaceutical company, has announced participation in two upcoming investor conferences: the William Blair Biotech Focus Conference on July 12-13, 2022, in New York, and the SVB Securities Biopharma Private Company Connect on July 20-21, 2022, offering virtual 1x1 meetings. The company specializes in pioneering oral therapies using defined bacterial consortia, targeting conditions such as C. difficile infection, inflammatory bowel diseases, and cancer. Vedanta boasts over 45 patents and a vast library of bacteria from the human microbiome.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences:

William Blair Biotech Focus Conference
Dates: July 12-13, 2022
Location: St. Regis Hotel, New York, NY
A pre-recorded fireside chat will be made available on the William Blair conference website starting on Monday, July 11, 2022.

SVB Securities Biopharma Private Company Connect
Dates: July 20-21, 2022
Virtual 1x1 meetings only

About Vedanta Biosciences

Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005193/en/

Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com



Investors

Chris Brinzey

+ 1 617 835 9304

Chris.Brinzey@westwicke.com

Source: Vedanta Biosciences

FAQ

What conferences is Vedanta Biosciences attending in July 2022?

Vedanta Biosciences will participate in the William Blair Biotech Focus Conference on July 12-13, 2022, in New York, and the SVB Securities Biopharma Private Company Connect on July 20-21, 2022.

What is the focus of Vedanta Biosciences' research?

Vedanta Biosciences focuses on developing oral therapies based on defined bacterial consortia to treat conditions like C. difficile infections, inflammatory bowel diseases, and cancer.

Where can I find Vedanta Biosciences' fireside chat for the William Blair conference?

The pre-recorded fireside chat will be available on the William Blair conference website starting on July 11, 2022.

How many patents does Vedanta Biosciences hold?

Vedanta Biosciences controls a foundational portfolio of more than 45 patents related to its bacterial consortia therapies.

What is the significance of the bacteria used by Vedanta Biosciences?

The bacteria used by Vedanta are derived from the human microbiome and are designed to induce beneficial immune responses and fight pathogens.